PD-1/PD-L1 Inhibitors Market
Number of pages: 100 | Report Format: PDF | Published date: May 10, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 44.85 billion |
|
Revenue Forecast in 2031 |
US$ 100.67 billion |
|
CAGR |
9.4% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product, Technology, Services, End User and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global PD-1/PD-L1 inhibitors market was valued at US$ 44.85 billion in 2022 and is expected to register a revenue CAGR of 9.4% to reach US$ 100.67 billion by 2031.
PD-1/PD-L1 Inhibitors Market Fundamentals
PD-1/PD-L1 inhibitors are a class of drugs used in cancer treatment that target the immune checkpoint pathway. PD-1 (programmed cell death protein 1) is a protein expressed on the surface of T cells, a type of immune cell that plays a critical role in recognizing and destroying cancer cells. PD-L1 (programmed death-ligand 1) is a protein expressed on the surface of tumor cells that can bind to PD-1 and suppress T-cell activity, allowing the tumor to evade the immune system. PD-1/PD-L1 inhibitors work by blocking the interaction between PD-1 and PD-L1, which releases the brakes on the immune system and allows T cells to recognize and attack cancer cells. This mechanism has shown promise in treating various cancers, including melanoma, non-small cell lung cancer, bladder cancer, and Hodgkin's lymphoma.
The research study on the PD-1/PD-L1 inhibitors market overview thoroughly analyzes the market, along with the aspects that either help or hinder the market's growth, such as its drivers, challenges, and opportunities. The research also discusses the list of businesses that operate in this market and their efforts to establish themselves as major players through expansion plans and innovative ideas. It also emphasizes current events that support the market's revenue expansion. The research also analyses how the COVID-19 pandemic has affected society.
This report is an important tool for the industry stakeholders to gather all the information about the market, customers, and competition. The report also provides the readers with valuable insights on the segmentation, regions, market size & forecast, revenue CAGRs, and other valuable data to help make informed strategic decisions. The study compiles information gathered from industry participants and specialists across the industry value chain. The report also taps into the qualitative and quantitative assessments by industry analysts. Our reports use different methods for estimating the market size and forecast, including secondary research, surveys and interviews, and statistical modeling. With these steps, our reports provide the most accurate market data. These datasets will cumulatively provide in-depth PD-1/PD-L1 inhibitors market forecast to the industry stakeholders.
[1212]
PD-1/PD-L1 Inhibitors Market Dynamics
The global incidence of cancer has been rising, and cancer remains a leading cause of death worldwide. As the prevalence of cancer continues to increase, there is a growing need for more effective and targeted treatments. According to GLOBOCAN 2020 report, around 19 million new cancer cases were detected, and approximately 10 million deaths were cases by cancer. Immunotherapy, including PD-1/PD-L1 inhibitors, has emerged as a promising approach to cancer treatment. Ongoing research and development in this field have led to the discovery of new targets and improved therapeutic strategies. While PD-1/PD-L1 inhibitors were initially approved for treating certain types of cancer, there is ongoing research and development aimed at expanding the use of these drugs to other indications. PD-1/PD-L1 inhibitors are part of a growing trend toward personalized medicine, which seeks to tailor treatments to individual patients based on their unique genetic and biological characteristics. Combination therapies involving PD-1/PD-L1 inhibitors and other drugs, such as chemotherapy or targeted therapies, are becoming increasingly common in cancer treatment. These combinations may offer improved patient outcomes by targeting multiple cancer growth and progression pathways. The market for PD-1/PD-L1 inhibitors is highly competitive, with several companies developing and marketing these drugs. This competition has led to the development of new formulations and the introduction of combination therapies, which may further drive demand for these drugs.
However, PD-1/PD-L1 inhibitors are among the most expensive cancer drugs restricting the growth of the PD-1/PD-L1 inhibitors market. PD-1/PD-L1 inhibitors can cause side effects, including fatigue, nausea, diarrhea, and skin rashes. In rare cases, these drugs can also cause severe autoimmune reactions, such as pneumonitis, colitis, and hepatitis, thus hindering the PD-1/PD-L1 inhibitors market growth.
PD-1/PD-L1 Inhibitors Market Ecosystem
PD-1/PD-L1 Inhibitors Market, by Type
PD-1/PD-L1 Inhibitors Market, by Application
PD-1/PD-L1 Inhibitors Market by Application
[36541]
The non-small cell lung cancer (NSCLC)segment accounted for the largest PD-1/PD-L1 inhibitors market share, with approximately 35% in 2022. Lung cancer is one of the most prevalent types of cancer worldwide. According to the WHO, in 2020, around 2.21 million lung cancer cases were diagnosed globally. The non-small cell lung cancer accounts for around 85% to 90% of lung cancer cases worldwide. This high incidence and prevalence of NSCLC make it a significant market opportunity for PD-1/PD-L1 inhibitors. Before the advent of PD-1/PD-L1 inhibitors, the standard of care for NSCLC was chemotherapy or radiation therapy, which have limited efficacy and significant side effects. PD-1/PD-L1 inhibitors offer a promising new treatment option for NSCLC patients, particularly those with advanced or metastatic disease. PD-1/PD-L1 inhibitors have demonstrated significant clinical efficacy in NSCLC, both as monotherapy and in combination with other drugs. In particular, the KEYNOTE-024 and KEYNOTE-042 trials showed that the PD-1 inhibitor pembrolizumab significantly improved overall survival in NSCLC patients with high PD-L1 expression compared to chemotherapy. NSCLC tumors often express high levels of PD-L1, which makes them particularly susceptible to PD-1/PD-L1 inhibitors. PD-L1 expression is also a predictive biomarker for response to PD-1/PD-L1 inhibitors, allowing physicians to identify patients most likely to benefit from these drugs.
Segmentation of the market refers to the division of the industry into subgroups based on factors such as product, technology, services, end user, etc. Market segmentation data helps businesses to understand the preferences and unique needs of different customer groups and develop targeted sales strategies. This information also helps in identifying potential PD-1/PD-L1 inhibitors market growth opportunities.
PD-1/PD-L1 Inhibitors Market by Region
North America has a high incidence and prevalence of various types of cancer, including lung cancer, melanoma, and bladder cancer. This high disease burden creates a significant market opportunity for PD-1/PD-L1 inhibitors, which have demonstrated clinical efficacy in treating these types of cancer. According to the WHO, in 2020, 2.2 million new cancer cases were diagnosed in U.S. North America has a strong healthcare infrastructure with well-established cancer diagnosis, treatment, and management systems. This infrastructure supports adopting and using PD-1/PD-L1 inhibitors, typically administered in specialized cancer centers. The regulatory environment for drug development and approval in North America is generally favorable, with clear pathways for regulatory approval and reimbursement. This regulatory environment supports the development and commercialization of PD-1/PD-L1 inhibitors and encourages investment in this market. North America has a strong research and development ecosystem, with many academic institutions, research organizations, and biopharmaceutical companies engaged in developing PD-1/PD-L1 inhibitors. This ecosystem supports the continued innovation and improvement of these drugs, driving growth in the regional market.
Based on the regions, the global PD-1/PD-L1 inhibitors market is segmented into:
Regional demarcation of the industry will provide information on geographic pockets regarding the PD-1/PD-L1 inhibitors’ market outlook, size, share, and growth rate. This data helps businesses evaluate the expansion potential into new regional markets, understand the competitive threats across different regions, and develop localized sales and expansion strategies.
Key Components of the Report
PD-1/PD-L1 Inhibitors Market Competitive Landscape
The market competitive landscape is performed by collecting and analyzing information about the key competitors, the present industry trends, and market dynamics. It includes information collection and analysis on factors such as products, pricing, geographic outreach, customer demographics, marketing strategies, and recent developments. Competitive landscape assessment will help businesses identify the current prevalent or potential opportunities and threats keeping in mind the PD-1/PD-L1 inhibitors industry trends.
PD-1/PD-L1 Inhibitors Market Strategic Developments
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Reasons to Buy this Report
PD-1/PD-L1 inhibitors are a class of drugs used in cancer treatment that target the immune checkpoint pathway. PD-1/PD-L1 inhibitors work by blocking the interaction between PD-1 and PD-L1, which releases the brakes on the immune system and allows T cells to recognize and attack cancer cells.
Asia Pacific can be considered as the key growth region due to the surge in PD-1/PD-L1 inhibitors devices industry trends in China, Japan, and the Indian subcontinent.
The PD-1/PD-L1 inhibitors devices market is expected to register a revenue CAGR of 9.4% during the forecast period from 2023 to 2031.
PD-1/PD-L1 inhibitors have shown promising results in combination with other cancer treatments, such as chemotherapy and radiation therapy. As researchers explore new combinations and dosing regimens, there may be opportunities to develop more effective treatment options for patients.
Key market players are investing significantly in research and development to develop new and improved PD-1/PD-L1 inhibitors and to expand their product portfolios into new indications and combinations with other cancer therapies.
The PD-1/PD-L1 inhibitors devices market was valued at US$ 44.85 billion in 2022
The estimated size of the global PD-1/PD-L1 inhibitors devices market in 2031 is US$ 100.67 billion.
The key players operating in the global pemphigus vulgaris market are Bristol-Myers Squibb Company, Merck & Co., Inc., Amgen Inc., AstraZeneca Plc, and Gilead Sciences, Inc.
The non-small cell lung cancer segment dominated the PD-1/PD-L1 inhibitors devices market.
*Insights on financial performance are subject to the availability of information in the public domain